ShareCast News for Animalcare Grp (ANCR)
Sun, 7th Mar 2010 10:44
Animalcare is ideally placed to take advantage of this trend. Formed in 2008 from the merger of a pet drugs business and a farm animal enterprise, the firm has three main divisions --medicines for pets, medical products for pets (such as injections, bandages and drips) and identity tags for pets and farm animals.
Animalcare has a June year-end and brokers forecast that pre-tax profits will show a 30% increase to £2.6m this year, accompanied by a 12% rise in the dividend to 2.8p. The shares are 121.5 but should go higher over the next two or three years. Buy says the Mail on Sunday.
Animalcare makes drugs for pets. CVS Group runs the vet practices where these drugs are administered. CVS shares are trading at 218p, a rise of 54% over the past nine months. The stock is unlikely to grow at a similar pace for the rest of the year, so investors who are keen to realise some cash should sell now. Otherwise, it is worth holding on to at least half as management is ambitious and the company has potential, the Mail on Sunday says.
Support services group Amec shares are trading on a December 2010 earnings multiple of 14.4 times, falling to 12.5 in 2011. However, if the cash is stripped out from the valuation, the group is trading on an ex-cash multiple of about 11 times, which looks cheap. Buy says the Telegraph.
Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.
A round-up of the biggest director buys today so far.
[5 Apr '13]Animalcare, a veterninary products group, has produced an anaemic set of full-year results with both turnover and profits below last year's levels.
[4 Oct '12]Also covered by this round-up are: Porvair, Oxford Pharmascience, Planet Payment, Hydro International, and International Greetings.
[24 May '12]Animalcare Group, a supplier of veterinary medicines, has said that its Project Quatto has received marketing authorisation from the Veterinary Medicines Directorate. The firm can now place the product on the market. The first sales are expected by the end of the current financial year.
[23 Mar '12]JP Morgan Russian Securities is trading at a discount to its net asset value of 727.53p as of March 15. It holds at 13.3% stake in Sberbank of Russia, 9.4% of retailer Magnit and 6.9% of miner Norilsk Nickel. Its largest investments are in the consumer staples, minerals and financial sectors.
[20 Mar '11]Pet medicines supplier Animalcare has sold its non-core livestock products business and this has removed the seasonality of the group's revenues.
[17 Feb '11]Veterinary medicines supplier Animalcare says its core operations grew revenues by 10% in the six months to December 2010.
[20 Jan '11]Animalcare has completed the sale and closure of its livestock products businesses and it will focus on its pet treatments business from now on.
[4 Oct '10]